Therefore, in MYC-driven tumors, targeting MYC-associated chromatin interactions, MYC expression, effector function, specific proteasomal degradation, and the MYC regulatory RNAs or taking advantage of synthetic lethal interactions may represent potential new strategies for cancer therapy (Figure 2, Table 2) [18,131,146]. This evidence concerns the gene MYC and cancer.